Medical Insights, Patient Stories & Latest Updates

For a long time, the development of RSV vaccines progressed slowly due to the complex structure of the virus. Recently, major breakthroughs in targeting the RSV fusion protein (F protein) have made both active immunity (vaccines) and passive immunity (monoclonal antibodies) a reality. These preventive measures have demonstrated high efficacy...

With the World Health Organization (WHO) once again declaring Mpox a "Public Health Emergency of International Concern" (PHEIC) in August 2024, this virus has returned to the public spotlight. Understanding its evolutionary characteristics and scientific prevention knowledge is crucial for reducing the risk of infection.